Here are 5 additional startups that got our attention
Machine learning to detect signs of colon cancer
Iterative Scopes develops technology using computer vision and machine learning to provide real-time, computer-aided detection of lesions and other signs of colon cancer.
In January, the company announced that it closed a $5.2 million seed round of financing, bringing its total funds raised to over $7 million at the time. –SW
Investors include: P5 Health Ventures, TAU Ventures, TMC Innovation, Wavemaker Partners
Walnut Creek, Calif.
Pharmaceutical therapy and patient monitoring for the detection of early illness
Oncodisc develops an implantable vascular access device embedded with an advanced sensor and communication technology.
In addition to facilitating the delivery of pharmaceutical therapy, the device monitors physiology for early detection of illness or treatment-related complications, according to the company. Oncodisc’s initial application centers around reducing the risks of cancer treatment. –SW
Providing intravascular ultrasound to measure flow lumen
Provisio develops sonic lumen tomography through intravascular ultrasound technology, providing real-time flow lumen dimensions in a platform that may be integrated into many currently used endovascular devices.
The company pulled down a $4 million funding round in January 2018 and followed that up with an additional $2 million raised in an August 2019 financing round. –SW
Minimizing blood trauma for chronic heart failure patients
Puzzle Medical Devices is a Canadian company specializing in the development of a minimally invasive long-term hemodynamic transcatheter pump. Puzzle Medical enables mechanical hemodynamic support to be more efficacious, safer, and more economical, resulting in increased accessibility, improved patient quality of life and reduction of the global economic burden related to the disease. To date, Puzzle Medical has successfully completed acute in vivo preclinical implantations, according to the company.
“This technology clearly answers an unmet need in the management of chronic heart failure patients,” Morristown Medical Center (N.J.) interventional cardiologist Dr. Philippe Généreux said in a statement. “I have been extremely impressed by the success achieved during the initial preclinical work and remain excited and confident about its future application in patients.”
On June 15, the company announced that it closed its first convertible debenture financing round for an undisclosed amount. –SW
Investors include: Pascal Labrecque
Developing fast, accurate and affordable diagnostic tests
Sherlock BioSciences is developing applications of Sherlock, a CRISPR-based method for detecting and quantifying genetic sequences, and Inspectr, a synthetic biology-based, instrument-free molecular diagnostic platform.
In May, the company earned FDA emergency use authorization for a SARS-CoV-2 diagnostic and has since garnered $7.5 million in grant money to accelerate the development of an at-home COVID-19 diagnostic. The company announced this month that it will collaborate with Integrated DNA Technologies (IDT) to enable large-scale manufacturing of the Sherlock CRISPR SARS-CoV-2 kit. ––SW
Investors include: Baidu Ventures, Northpond Ventures, Open Philanthropy Project